Literature DB >> 1506854

Dystrophin deficiency causes lethal muscle hypertrophy in cats.

F P Gaschen1, E P Hoffman, J R Gorospe, E W Uhl, D F Senior, G H Cardinet, L K Pearce.   

Abstract

Two 5-month-old male Domestic Shorthair littermates showed general skeletal muscle hypertrophy, multifocal submucosal lingual calcification with lingual enlargement, and excessive salivation. Both cats had a reduced level of activity, walked with a stiff gait, and tended to "bunny hop" when they ran. These clinical features were similar to those of previously reported dystrophin-deficient cats. Using multiple dystrophin antibodies, we found that the cats described in this report also showed marked dystrophin deficiency. The histopathology was remarkable for hypertrophy and splitting of fibers, and progressive accumulation of calcium deposits within the muscle. There was little or no endomysial fibrosis at 2 years of age. The natural history of dystrophin-deficiency in cats has not been described: both previous cats had been euthanized at 2 years of age prior to experiencing any life-threatening problems. At 6 months of age, one of the new cats developed megaesophagus because of severe progressive hypertrophy of the diaphragmatic muscles. The diaphragm completely occluded the esophagus, and the cat was euthanized for humane reasons. The second cat remained in good condition until age 18 months when it developed acute renal failure attributed to severe prolonged dehydration and hyperosmolality. The cat recovered after receiving supportive treatment but was unable to maintain fluid homeostasis. The insufficient water intake was attributed to glossal hypertrophy and dysfunction. At age 2 years, the cat received regular subcutaneous injections of low-sodium fluids to maintain proper hydration. The clinical consequence of dystrophin deficiency in cats is lethal muscle hypertrophy. We have called the feline disease "hypertrophic feline muscular dystrophy" (HFMD).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1506854     DOI: 10.1016/0022-510x(92)90022-d

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  33 in total

Review 1.  Understanding dystrophinopathies: an inventory of the structural and functional consequences of the absence of dystrophin in muscles of the mdx mouse.

Authors:  J M Gillis
Journal:  J Muscle Res Cell Motil       Date:  1999-10       Impact factor: 2.698

2.  A computerized MRI biomarker quantification scheme for a canine model of Duchenne muscular dystrophy.

Authors:  Jiahui Wang; Zheng Fan; Krista Vandenborne; Glenn Walter; Yael Shiloh-Malawsky; Hongyu An; Joe N Kornegay; Martin A Styner
Journal:  Int J Comput Assist Radiol Surg       Date:  2013-01-09       Impact factor: 2.924

3.  Utrophin is lacking at the neuromuscular junctions in the extraocular muscles of normal cat: artefact or true?

Authors:  Maziar Assadi; Markus Müntener
Journal:  Histochem Cell Biol       Date:  2005-02-24       Impact factor: 4.304

Review 4.  Porcine models of muscular dystrophy.

Authors:  Joshua T Selsby; Jason W Ross; Dan Nonneman; Katrin Hollinger
Journal:  ILAR J       Date:  2015

Review 5.  Dystrophin-deficient large animal models: translational research and exon skipping.

Authors:  Xinran Yu; Bo Bao; Yusuke Echigoya; Toshifumi Yokota
Journal:  Am J Transl Res       Date:  2015-08-15       Impact factor: 4.060

6.  Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9.

Authors:  Yongchang Chen; Yinghui Zheng; Yu Kang; Weili Yang; Yuyu Niu; Xiangyu Guo; Zhuchi Tu; Chenyang Si; Hong Wang; Ruxiao Xing; Xiuqiong Pu; Shang-Hsun Yang; Shihua Li; Weizhi Ji; Xiao-Jiang Li
Journal:  Hum Mol Genet       Date:  2015-04-09       Impact factor: 6.150

7.  Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats.

Authors:  Paul T Martin; G Diane Shelton; Peter J Dickinson; Beverly K Sturges; Rui Xu; Richard A LeCouteur; Ling T Guo; Robert A Grahn; Harriet P Lo; Kathryn N North; Richard Malik; Eva Engvall; Leslie A Lyons
Journal:  Neuromuscul Disord       Date:  2008-11-05       Impact factor: 4.296

Review 8.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

Review 9.  The Evolving Genome Project: current and future impact.

Authors:  E P Hoffman
Journal:  Am J Hum Genet       Date:  1994-01       Impact factor: 11.025

10.  A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.

Authors:  Gemma L Walmsley; Virginia Arechavala-Gomeza; Marta Fernandez-Fuente; Margaret M Burke; Nicole Nagel; Angela Holder; Rachael Stanley; Kate Chandler; Stanley L Marks; Francesco Muntoni; G Diane Shelton; Richard J Piercy
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.